BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease

In four patients with severe autoimmune disease, teclistimab, a bispecific antibody to B-cell maturation antigen and CD3, resulted in autoantibody reduction and clinical response after short-term follow-up.

​   The New England Journal of Medicine: Search Results in Dermatology